Palvella Therapeutics (PVLA) EBITDA Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported EBITDA Margin of 5150.94% for Q1 2024, down 446112.0% year-over-year from N/an in Q2 2023, and down 7221.07% on a QoQ basis from 70.36% in Q3 2023.
Palvella Therapeutics (PVLA) has 11 years of EBITDA Margin data on file, last reported at 5150.94% in Q1 2024.
- Quarterly EBITDA Margin fell 446112.0% year-over-year to 5150.94% in Q1 2024, while the trailing twelve-month figure through Sep 2024 was 152.95% (up 23196.0% YoY) and the FY2021 annual result came in at 159.68%, down 3851.0% from the prior year.
- EBITDA Margin fell to 5150.94% in Q1 2024 per PVLA's latest filing, from 70.36% in the prior quarter.
- Across five years, EBITDA Margin topped out at 21.27% in Q2 2023 and bottomed at 5150.94% in Q1 2024.
- The 5-year median for EBITDA Margin is 307.55% (2022), against an average of 849.47%.
- The widest annual swing landed in 2023, when EBITDA Margin soared 374243 bps; it then sank 446112 bps in 2024.
- Tracing PVLA's EBITDA Margin over 5 years: stood at 741.24% in 2020, then soared by 75 bps to 187.69% in 2021, then slumped by 1931 bps to 3812.79% in 2022, then jumped by 98 bps to 70.36% in 2023, then plunged by 7221 bps to 5150.94% in 2024.
- Per Business Quant, the three latest PVLA EBITDA Margin figures stand at 5150.94% (Q1 2024), 70.36% (Q3 2023), and 21.27% (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -5,150.94% |
| Sep 30, 2023 | -70.36% |
| Jun 30, 2023 | 21.27% |
| Mar 31, 2023 | -689.82% |
| Sep 30, 2022 | -3,812.79% |
| Jun 30, 2022 | -307.55% |
| Mar 31, 2022 | -45.29% |
| Dec 31, 2021 | -187.69% |
| Sep 30, 2021 | -580.45% |
| Jun 30, 2021 | -608.58% |
| Mar 31, 2021 | -28.33% |
| Dec 31, 2020 | -741.24% |
| Sep 30, 2020 | -476.39% |
| Jun 30, 2020 | -42.57% |
| Mar 31, 2020 | -21.33% |
| Dec 31, 2019 | -67.70% |
| Sep 30, 2019 | -3.85% |
| Jun 30, 2019 | -232.73% |
| Mar 31, 2019 | -110.26% |
| Dec 31, 2018 | -1,935.17% |
| Sep 30, 2018 | -79.47% |
| Jun 30, 2018 | 27.34% |
| Mar 31, 2018 | -240.66% |
| Dec 31, 2017 | 29.10% |
| Sep 30, 2017 | -189.81% |
| Jun 30, 2017 | -578.90% |
| Mar 31, 2017 | -591.44% |
| Dec 31, 2016 | -234.91% |
| Sep 30, 2016 | -786.99% |
| Jun 30, 2016 | -540.19% |
| Mar 31, 2016 | -351.40% |
| Dec 31, 2015 | 606.08% |
| Sep 30, 2015 | -935.79% |
| Jun 30, 2015 | -2,205.66% |
| Mar 31, 2015 | -1,700.82% |
| Sep 30, 2014 | -9,832.80% |
| Jun 30, 2014 | -396.71% |